BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28726181)

  • 1. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?
    Grillo F; Valle L; Ferone D; Albertelli M; Brisigotti MP; Cittadini G; Vanoli A; Fiocca R; Mastracci L
    Endocrine; 2017 Sep; 57(3):494-502. PubMed ID: 28726181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
    Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors.
    Murphy CE; McCormick KA; Shankaran V; Reddi DM; Swanson PE; Upton MP; Papanicolau-Sengos A; Khor S; Westerhoff M
    Pancreas; 2017; 46(10):1359-1365. PubMed ID: 29040195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
    Bellizzi AM
    Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
    Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
    Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?
    Rebours V; Cordova J; Couvelard A; Fabre M; Palazzo L; Vullierme MP; Hentic O; Sauvanet A; Aubert A; Bedossa P; Ruszniewski P
    Dig Liver Dis; 2015 Nov; 47(11):973-7. PubMed ID: 26169284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 18. Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features.
    Tang C; Gong L; Zou W; Zhang J; Zhou Y; Wu X; Lu F; Ouyang C; Liu X
    Oncol Rep; 2016 Dec; 36(6):3343-3352. PubMed ID: 27748940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.